Inovio Pharmaceuticals, Inc. (INO) 追踪市盈率为负值 -6.0, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 3.6 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -16.78%, 前瞻盈利收益率 28.01%. PEG 0.06 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 51/100 其中 3/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -82.5 | -0.61 | 49.32 | 171.91 | - |
| 2017 | -45.9 | -6.63 | 28.46 | 95.99 | 0.56% |
| 2018 | -45.7 | 16.46 | 50.99 | 145.42 | - |
| 2019 | -41.3 | 5.43 | 1,436.66 | 1,200.19 | - |
| 2020 | -105.5 | -10.24 | 38.08 | 2,369.48 | - |
| 2021 | -42.3 | -1.29 | 32.16 | 7,241.33 | - |
| 2022 | -1.3 | 0.00 | 1.67 | 36.27 | - |
| 2023 | -1.0 | 0.02 | 1.16 | 163.10 | - |
| 2024 | -0.5 | 0.01 | 0.73 | 228.26 | - |
| 2025 | -9.6 | 0.18 | 33.86 | 12,485.24 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-1.01 | $35.37M | $-73.74M | -208.5% |
| 2017 | $-1.08 | $42.22M | $-88.21M | -208.9% |
| 2018 | $-1.05 | $30.48M | $-96.97M | -318.1% |
| 2019 | $-14.65 | $4.11M | $-120.55M | -2931.8% |
| 2020 | $-16.64 | $7.41M | $-215.09M | -2902.2% |
| 2021 | $-17.55 | $1.77M | $-305.38M | -17207.1% |
| 2022 | $-14.47 | $10.26M | $-287.66M | -2803.1% |
| 2023 | $-6.09 | $832.01K | $-135.12M | -16239.9% |
| 2024 | $-3.95 | $217.76K | $-107.25M | -49254.3% |
| 2025 | $-1.81 | $65.34K | $-84.95M | -130000% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-1.21 | $-1.56 – $-0.93 | $10.88M | $733.46K – $30.45M | 4 |
| 2027 | $-0.53 | $-1.04 – $-0.01 | $68.4M | $44.25M – $92.55M | 3 |
| 2028 | $0.65 | $0.06 – $1.11 | $174.85M | $174.85M – $174.85M | 3 |
| 2029 | $1.09 | $0.44 – $2.01 | $235.3M | $126.7M – $387.83M | 1 |
| 2030 | $1.25 | $0.50 – $2.31 | $254.64M | $137.11M – $419.71M | 1 |
